RETA News and Press, Reata Pharmaceuticals Inc.

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...

2023-09-21 10:36:52 ET More on Biogen, Reata, etc. Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact...

Shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) traded at a new 52-week high today and are currently trading at $172.29. So far today, approximately 68,981 shares have been exchanged, as compared to an average 30-day volume of 638.97k shares. Reata Pharmaceuticals, Inc., a clinical-stage...

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, annou...

NEW YORK, NY / ACCESSWIRE / September 18, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PFSweb, Inc. (NASDAQ:PFSW)'s sale...

2023-09-15 15:00:00 ET More on the markets Key Region Of Support Sides With SPY Bullish Case Market Crosswinds And Nasdaq Looking Better Than Dow The Fed's rate-hike cycle has 'most assuredly ended' -- Lawrence Fuller Fund managers finally embrace U.S. stocks...

2023-09-12 13:26:27 ET More on Reata Pharmaceuticals Seeking Alpha’s Quant Rating on Reata Pharmaceuticals Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward San...